First- and third- generation EGFR inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatologic reactions.

First- and third- generation EGFR inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatologic reactions.
Br J Dermatol. 2020 Jun 01;:
Authors: Vasavda C, Ho BK, Zhang DY, Williams KA, Kaffenberger BH, Kwatra SG, Kwatra MM
Abstract
Epidermal growth factor receptor (EGFR) inhibitors are used to treat several malignancies but notoriously exert dermatologic toxicities, reducing patient adherence. Despite targeting the same receptor, different EGFR inhibitors exhibit distinct toxicities. Up to 90% of patients on EGFR inhibitors present with a papulopustular rash, with varying severity and frequency depending on the inhibitor. Some first-generation inhibitors, such as erlotinib and gefitinib, affect hair follicles, resulting in alopecia, hirsutism, and/or trichomegaly. Erlotinib and gefitinib also often elicit pruritus, paronychia, xerosis, and mucositis.
PMID: 32479649 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - May 31, 2020 Category: Dermatology Authors: Vasavda C, Ho BK, Zhang DY, Williams KA, Kaffenberger BH, Kwatra SG, Kwatra MM Tags: Br J Dermatol Source Type: research